Pfizer Commended For Leadership In Addressing Climate Change

Pfizer Inc.Pfizer Inc. (NYSE: PFE) has been commended by the Carbon Disclosure Project (CDP) for its approach to addressing climate change. For the fourth consecutive year, CDP named Pfizer to its Carbon Disclosure Leadership Index, which highlights the company's climate change disclosure practices. Pfizer was ranked highest among the S&P 500 health care companies on the index - the third consecutive year that Pfizer made the S&P list - and ranked fourth on CDP's Global 500 health care companies list.

"Pfizer's commitment to reducing our impact on the environment fits perfectly with our mission to address health needs worldwide," said Nat Ricciardi, president of Pfizer Global Manufacturing and the company's leadership sponsor of its Environmental Sustainability Program. "I'm especially proud of the innovative ideas and hard work by our employees to achieve these reductions and contribute to Pfizer's sustainable practices."

According to Mr. Ricciardi, Pfizer exceeded its initial goal to reduce greenhouse gas emissions by achieving a 43 percent reduction relative to revenue between 2000 and 2007. The company's second goal, to be achieved between 2007 and the end of 2012, is to cut greenhouse gases by 20 percent on an absolute basis.

"We've made significant progress on our current goal," said Mr. Ricciardi. "Energy teams at Pfizer facilities around the world completed more than 500 conservation-related projects in 2009, greatly reducing Pfizer's annual energy usage while cutting C02 emissions by 120,000 metric tons."

Examples of Pfizer projects include installation of a biomass boiler at a plant in Freiburg, Germany; start-up of a five megawatt cogeneration unit in Grange Castle, Ireland; installation of high efficiency chiller and "free-cooling" heat exchanger at a commercial facility in Peapack, N.J.; reduced demand on HVAC systems through targeted hours of use and temperature settings at a research site in Sandwich, United Kingdom; and installation of energy-efficient light fixtures, occupancy sensors and timers at Pfizer facilities in Kalamazoo, Mich.

Paul Dickinson, Chief Executive of CDP, said the Carbon Disclosure Leadership Index recognizes companies that demonstrate good internal data management practices for understanding greenhouse gas emissions, including energy use. "Companies that make this index have also demonstrated clear consideration of how climate change is and will impact their business," Mr. Dickinson said. "As companies' understanding of climate change issues grows, they are better placed to take positive action to manage and mitigate its risks."

CDP is a not-for-profit coalition of 534 institutional investors with $64 trillion in assets under management. This index, a key component of CDP's annual S&P 500 Report, highlights the constituent companies within the S&P 500 Index which have displayed the most professional approach to corporate governance in respect of climate change disclosure practices. Companies are scored on their climate change disclosure and high scores indicate good internal data management and understanding of climate change related issues affecting the company.

The S&P 500 Report, including names of companies featured in the Carbon Disclosure Leadership Index, can be found at www.cdproject.net.

Pfizer Inc.: Working together for a healthier world™
At Pfizer, we apply science and our global resources to improve health and well-being at every stage of life. We strive to set the standard for quality, safety and value in the discovery, development and manufacturing of medicines for people and animals. Our diversified global health care portfolio includes human and animal biologic and small molecule medicines and vaccines, as well as nutritional products and many of the world's best-known consumer products. Every day, Pfizer colleagues work across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases of our time. Consistent with our responsibility as the world's leading biopharmaceutical company, we also collaborate with health care providers, governments and local communities to support and expand access to reliable, affordable health care around the world. For more than 150 years, Pfizer has worked to make a difference for all who rely on us. To learn more about our commitments, please visit us at www.pfizer.com.

Most Popular Now

In wine, there's health: Low levels of alcohol goo…

While a couple of glasses of wine can help clear the mind after a busy day, new research shows that it may actually help clean the mind as well. The new study, which appe...

Sanofi to acquire Ablynx for €3.9 Billion

Sanofi and Ablynx, a biopharmaceutical company engaged in the discovery and development of Nanobodies®, entered into a definitive agreement under which Sanofi will offer ...

Repurposed drug found to be effective against Zika…

In both cell cultures and mouse models, a drug used to treat Hepatitis C effectively protected and rescued neural cells infected by the Zika virus - and blocked transmiss...

More stroke patients may receive crucial treatment…

More patients could be eligible for critical treatments to remove or dissolve blood clots that cause strokes, according to a new treatment guideline issued by the America...

Interim publications of randomized trials make new…

Early results from randomized trials are sometimes published before the trial is completed. The results of such interim publications may generate a great deal of interest...

Drug trial protocol redactions by industry sponsor…

New research published by the Journal of the Royal Society of Medicine exposes the extent of redactions in protocols for industry-sponsored randomised drug trials. Trial ...

Advanced Accelerator Applications receives FDA ap…

Novartis AG (NYSE: NVS) announced that Advanced Accelerator Applications, a subsidiary of Novartis Groupe S.A., has received US Food and Drug Administration (FDA) approva...

Blood vessel-on-a-chips show anti-cancer drug effe…

Researchers at the Institute of Industrial Science (IIS), the University of Tokyo, CNRS and INSERM, report a new organ-on-a-chip technology for the study of blood vessel ...

Roche reports good results in 2017

In 2017, Group sales rose 5% to CHF 53.3 billion. Core operating profit grew 3% and Core EPS increased 5%, reflecting the good underlying business performance. On an IFRS...

FDA approves new treatment for certain digestive t…

The U.S. Food and Drug Administration today approved Lutathera (lutetium Lu 177 dotatate) for the treatment of a type of cancer that affects the pancreas or gastrointesti...

Guidelines extended to improve the use of feedback…

Researchers have recommended changes to international guidelines used in the development of clinical trials in an effort to gain information about the impact of the treat...

Cells of 3 advanced cancers die with drug-like com…

Researchers at Southern Methodist University have discovered three drug-like compounds that successfully reverse chemotherapy failure in three of the most commonly aggres...

Pharmaceutical Companies

[ A | B | C | D | E | F | G | H | I | J | K | L | M | N | O | P | Q | R | S | T | U | V | W | X | Z ]